Improving the care of diabetic patients on peritoneal dialysis

Contributions to Nephrology

Volumn 178, Issue , 2012, Pages 271-277

  Dalal, Pranav ^a   Misra, Madhukar ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY; MORTALITY; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS;

BLOOD GLUCOSE; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS;

EID: 84862148002     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (43)

1. US Renal Data System UADR: Atlas of Chronic Kidney Disease and End- Stage Renal Disease in United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011.
2. US Renal Data System UADR: Atlas of Chronic Kidney Disease and End- Stage Renal Disease in United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
3. Vonesh EF, Snyder JJ, Foley RN, Collins AJ: Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int Suppl 2006;103:S3- S11.
4. Liem YS, Wong JB, Hunink MG, de Charro FT, Winkelmayer WC: Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. Kidney Int 2007;71:153- 158.
5. Serkes KD, Blagg CR, Nolph KD, Vonesh EF, Shapiro F: Comparison of patient and technique survival in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis: a multicenter study. Perit Dial Int 1990;10:15- 19.
6. Van Biesen W, Vanholder RC, Veys N, Dhondt A, Lameire NH: An evaluation of an integrative care approach for end- stage renal disease patients. J Am Soc Nephrol 2000;11:116- 125.
7. van der Wal WM, Noordzij M, Dekker FW, et al: Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant Sep 2011;26:2978- 2983.
8. Bargman JM, Thorpe KE, Churchill DN: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158- 2162.
9. Wang AY, Wang M, Woo J, et al: Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol Aug 2004;15:2186- 2194.
10. Moist LM, Port FK, Orzol SM, et al: Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol Mar 2000;11:556- 564.
11. Liao CT, Chen YM, Shiao CC, et al: Rate of decline of residual renal function is associated with all- cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transplant Sep 2009;24:2909- 2914.
12. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC: Effects of an angiotensin- converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003;139:105- 112.
13. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H: Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004;43:1056- 1064.
14. Medcalf JF, Harris KP, Walls J: Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int Mar 2001;59:1128- 1133.
15. Williams JD, Topley N, Craig KJ, et al: The Euro- Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408- 418.
16. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM: Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008;73:200- 206.
17. Santamaria B, Sanz A, Justo P, et al: Peritoneal defence - lessons learned which apply to diabetes complications. Nephrol Dial Transplant Jul 2006;21(suppl 2):ii12- ii15.
18. Holley J, Bernardini J, Piraino B: Catheter infections in insulindependent diabetics on continuous ambulatory peritoneal dialysis. Perit Dial Int 1991;11:347- 350.
19. Digenis GE, Abraham G, Savin E, et al: Peritonitis- related deaths in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1990;10:45- 47.
20. Han SH, Lee SC, Ahn SV, et al: Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant Sep 2007;22:2653- 2658.
21. Mujais S: Microbiology and outcomes of peritonitis in North America. Kidney Int Suppl 2006;103:S55- S62.
22. Gan HB, Chen MH, Lindholm B, Wang T: Volume control in diabetic and nondiabetic peritoneal dialysis patients. Int Urol Nephrol 2005;37:575- 579.
23. Quan L, Xu Y, Luo SP, Wang L, LeBlanc D, Wang T: Negotiated care improves fluid status in diabetic peritoneal dialysis patients. Perit Dial Int 2006;26:95- 100.
24. Takatori Y, Akagi S, Sugiyama H, et al: Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial. Clin J Am Soc Nephrol 2011;6:1337- 1344.
25. Heimburger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B: Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990;38:495- 506.
26. Honda K, Hamada C, Nakayama M, et al: Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol 2008;3:720- 728.
27. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB: Angiotensin II mediates high glucose- induced TGF- beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005;25:38- 47.
28. Nessim SJ, Perl J, Bargman JM: The renin- angiotensin- aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum? Kidney Int 2010;78:23- 28.
29. Sauter M, Cohen CD, Wornle M, Mussack T, Ladurner R, Sitter T: ACE inhibitor and AT1- receptor blocker attenuate the production of VEGF in mesothelial cells. Perit Dial Int 2007;27:167- 172.
30. Kolesnyk I, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT: A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 2009;24:272- 277.
31. Fang W, Oreopoulos DG, Bargman JM: Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant Nov 2008;23:3704- 3710.
32. Davies SJ, Brown EA, Frandsen NE, et al: Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int Apr 2005;67:1609- 1615.
33. Nakao A, Nakao K, Takatori Y, et al: Effects of icodextrin peritoneal dialysis solution on the peritoneal membrane in the STZ- induced diabetic rat model with partial nephrectomy. Nephrol Dial Transplant 2010;25:1479- 1488.
34. Sandoval P, Loureiro J, Gonzalez-Mateo G, et al: PPAR- gamma agonist rosiglitazone protects peritoneal membrane from dialysis fluid- induced damage. Lab Invest 2010;90:1517- 1532.
35. Duong U, Mehrotra R, Molnar MZ, et al: Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol 2011;6:1041- 1048.
36. Huang CC: Treatment targets for diabetic patients on peritoneal dialysis: any evidence? Perit Dial Int 2007;27(suppl 2):S176- S179.
37. Szeto CC, Chow KM, Leung CB, et al: Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis. Nephrol Dial Transplant 2007;22:1697- 1702.
38. Quellhorst E: Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol 2002;13(suppl 1): S92- S96.
39. Diaz-Buxo JA, Burgess WP, Greenman M, Chandler JT, Farmer CD, Walker PJ: Visual function in diabetic patients undergoing dialysis: comparison of peritoneal and hemodialysis. Int J Artif Organs Sep 1984;7:257- 262.
40. Rottembourg J, Bellio P, Maiga K, Remaoun M, Rousselie F, Legrain M: Visual function, blood pressure and blood glucose in diabetic patients undergoing continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985;21:330- 334.
41. Richardson D, Ford D, Gilg J, Williams AJ: UK Renal Registry 11th Annual Report (December 2008). Chapter 9: Haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centrespecific analyses. Nephron Clin Pract 2009;111(suppl 1):c149- c183.
42. Tokodai K, Amada N, Kikuchi H, Haga I, Takayama T, Nakamura A: Outcomes of renal transplantation after end- stage renal disease due to diabetic nephropathy: a singlecenter experience. Transplant Proc 2012;44:77- 79.
43. Goldfarb-Rumyantzev AS, Hurdle JF, Scandling JD, Baird BC, Cheung AK: The role of pretransplantation renal replacement therapy modality in kidney allograft and recipient survival. Am J Kidney Dis Sep 2005;46:537- 549.